NeuroTrials Research Inc

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Obstructive sleep apnoea7 trials
• Narcolepsy4 trials
• Obesity4 trials
• Alzheimer disease2 trials
• Migraine2 trials
• Type 2 diabetes2 trials
• Essential tremor1 trial
• High blood pressure1 trial
• Insomnia1 trial
• Osteoarthritis1 trial
• Parkinson disease1 trial

Phase

• Phase 28 trials
• Phase 38 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Completed12 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Jazz Pharmaceuticals3 trials
• Apnimed1 trial
• Avadel1 trial
• Biohaven Therapeutics Ltd.1 trial
• and 9 more

Running trials

• Recruiting

  A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

  NCT07675135· Phase 3· Harmony Biosciences Management, Inc.· Source

  Contact: Shriya Parekh

• Recruiting

  AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

  NCT07571109· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

  NCT07493265· Phase 2· Eisai Inc.· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Apnimed· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Narcolepsy2 recruiting
• Obstructive sleep apnoea2 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

  NCT06785454· Phase 2· Mineralys Therapeutics Inc.· Source

• Completed

  Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

  NCT06603623· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

  NCT06146101· Phase 2/3· Incannex Healthcare Ltd· Source

• Completed

  A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

  NCT05875974· Phase 4· Jazz Pharmaceuticals· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

  NCT05642442· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

  NCT05423717· Phase 2· Idorsia Pharmaceuticals Ltd.· Source

• Completed

  Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

  NCT05412004· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Seltorexant in Participants With Probable Alzheimer's Disease

  NCT05307692· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

  NCT05122650· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  An Open Label Study of FT218 in Subjects With Narcolepsy

  NCT04451668· Phase 3· Avadel· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source